Clinical trial
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00476931 · Sangamo Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00476931 |
|---|---|
| Title | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy |
| Official title | A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity |
| Lead sponsor | Sangamo Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1, Type 2, Diabetic Polyneuropathy |
| Intervention type | Biological, Other |
| Interventions | SB-509, Placebo |
| Enrollment | 91 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | May 22, 2007 |
| Last update posted | Nov 1, 2012 |
| Countries | Mexico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: